Dorzolamide+Timolol Multidose Preservative-free vs Dorzolamida+Timolol BAK Preserved Efficacy and Safety

Inclusion Criteria:

• Older than 18 years old

• Patients with POAG and OH

• PIO < 20 mmHg

• Under treatment with Dorzolamide + Timolol BAK preserved at least 6 month after

• OSDI > 13 & one of these ocular signs (BUT <6sec or Schirmer test < 5 mm/5min orcorneal staining positive)

• Corneal thickness between 520-580 um.

Exclusion Criteria:

• Patient with severe respiratory diseases (asthma, COPD and other bronchospacticdiseases).

• Patient with cardiovascular diseases (Sinus Bradycardia, AV Block, Cardiac Failure,Cardiogenic Shock).

• Severe renal impairment (CrCl <30 mL/min)

• Progressive diseases of the retina other than glaucoma

• Inflammation and/or infecctions active

• Ocular surface syndrome other than Ocular Surface disease

• Eyelid disorder

• Systemic adminsitration of Betablockers or carbonic anhydrase inhibitors

• Patient that requires another antigluacomatous eye drop other than fixed combinationof Dorzolamide/Timolol

• Patients who use regularly lubricant eye drops

• Patient who use regularly contact lenses

• Patient with autoinmune diseases

• Patients who underwent kerato-refractive laser procedures, cornea or corneal surfacesurgery, including, but not limited to, LASIK and PRK, within 6 months prior to thebaseline visit.

• Patients who have undergone a laser procedure or intraocular surgery or extraocularin either eye within 6 months prior to the baseline visit.

• Patients with severe central visual field loss in either eye based onclinicaljudgment of the investigator. For the Humphrey and Octopus perimeters, the severeloss The visual field is defined as a sensitivity less than or equal to 10 dB in atleast two(2) of the four (4) visual field test points closest to the fixation point

• Patients with known hypersensitivity to any of the components of bothdrugs understudy.

• Pregnant or lactating women.

• Women of childbearing age who are not using a contraceptive method.